The following video is from Wednesday's Investor Beat, in which host Chris Hill and analysts Jason Moser and Lyons George dissect the hardest-hitting investing stories of the day.
In this installment of Investor Beat, our analysts explain why they're watching JPMorgan Chase (NYSE: JPM ) and Facebook (NASDAQ: FB ) .
After the world's most-hyped IPO turned out to be a dud, most investors probably don't even want to think about shares of Facebook. But there are things every investor needs to know about this company. We've outlined them in our newest premium research report. There's a lot more to Facebook than meets the eye, so read up on whether there is anything to "like" about it today, and we'll tell you whether we think Facebook deserves a place in your portfolio. Access your report by clicking here.
The relevant video segment can be found between 0:16 and 2:57.
Oriental Financial Group Inc., a financial holding company, provides various banking and financial services to mid and high net worth individuals, and families, including professionals and owners of small and mid-sized businesses primarily in Puerto Rico. It operates in three segments: Banking, Wealth Management, and Treasury. The Banking segment offers commercial and consumer lending, saving and time deposit products, financial planning, and corporate and individual trust services. It also provides mortgage lending products that include the origination and purchase of residential mortgage loans. As of October 25, 2011, this segment operated 30 branches in Puerto Rico. The Wealth Management segment offers securities brokerage, trust services, retirement planning, insurance, pension administration, and other wealth management services. Its securities brokerage services include various investment alternatives, such as tax-advantaged fixed income securities, mutual funds, sto cks, and bonds to retail and institutional clients. This segment also provides public offerings and private placements of debt and equity securities, underwriting, and merger and acquisition and financial restructuring advisory services. In addition, it engages in insurance agency services and administration of retirement plans in the United States, Puerto Rico, and the Caribbean. The Treasury segment is involved in various treasury related functions with an investment portfolio consisting of mortgage-backed securities, obligations of U.S. government sponsored agencies, Puerto Rico government and agency obligations, structured credit investments, and money market instruments. The company was founded in 1964 and is based in San Juan, Puerto Rico.
Advisors' Opinion: - [By John Udovich]
For investors looking for exposure to the US commonwealth of Puerto Rico, banking stocks Doral Financial Corp (NYSE: DRL), First Bancorp (NYSE: FBP), OFG Bancorp (NYSE: OFG) and Popular Inc (NASDAQ: BPOP) offer the best bet as these Puerto Rico stocks trade on major US exchanges rather than the OTC. However, it should be mentioned that there has been a slowdown in Puerto Rico�� economy which has also shrunk in five of the past seven fiscal years. Then last�February, Puerto Rico�� debt was cut to speculative grade by the three largest credit-rating companies while�Governor Alejandro Garcia Padilla has proposed a series of budget cuts to help tackle the island�� mounting debt load -including the freezing public workers��salaries and the closing about 100 schools.
- [By Paul Ausick]
The third recommended multinational is another Puerto Rican bank, OFG Bancorp (NYSE: OFG). A recent dividend increase could indicate a share buyback for next year. The bank raised its EPS guidance in every quarter of 2013. This small cap bank closed at $16.82 on Friday in a 52-week range of $12.86 to $19.33. The Sterne Agee price target on the stock is $23.00, yielding a potential upside of almost 79%. The EPS estimate for 2014 is $2.05 and the stock�� forward multiple for 2014 is a low 8.3 from the firm while the consensus multiple is 9.45.
- [By Marc Bastow]
Diversified financial services company OFG Bancorp (OFG) raised its quarterly dividend 33% to 8 cents per share, payable on Jan. to shareholders of record as of Dec. 31.
OFG Dividend Yield: 1.8%
Best Healthcare Equipment Stocks To Invest In 2014: Bayer AG (BAYRY.PK)
Bayer AG is a management holding company. The Company�� business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals. Bayer CropScience is engaged in the crop protection and non-agricultural pest control. Bayer MaterialScience supplies polymers, and develops solution for a range of applications. In November 2009, Bayer MaterialScience acquired the polymer coatings business from Lombard Medical Technologies PLC. On November 2, 2009, it acquired Athenix Corporation. On October 1, 2009, it acquired two dermatology product lines from SkinMedica, Inc., Carlsbad, California, United States. On June 25, 2009, it acquired the remaining 10% interest in Bayer Polymers (Shanghai) Co. Ltd., China. In May 2009, it acquired the remaining 49% interest in Berlimed, s.a., Spain, from Juste s.a. Quimica Farmac茅utica (Juste), and in return sold its 51% interest of Justesa Imagen, s.a., Spain, to Juste. In May 2009, it also sold the Thermoplastics Testing Center, Krefeld, Germany, to Underwriters Laboratories Inc. In March 2010, the Company announced that its Bayer MaterialScience LLC has acquired Artificial Muscle, Inc, a company active in electroactive polymers for the consumer electronics industry.
Bayer HealthCare
The Company researches, develops, manufactures pharmaceutical and medical products. Bayer HealthCare operates in four operating divisions: Animal Health, which is engaged in manufacture of veterinary medicines and grooming products; Bayer Schering Pharma, which is engaged in manufacture of prescription medicines; Consumer Care, which is engaged in the manufacture of over-the-counter medicines and dietary supplements, and Medical Care, which is engaged in manufacture of blood glucose monitoring devices and contrast agent injecti! on systems. Its products for farm animals include Baytril. Its products for companion animals include Advantage/Advantix and Baytril. Its drug discovery in the pharmaceuticals segment focuses on the areas of cardiology, oncology,
women�� healthcare and diagnostic imaging.
Bayer CropScience
CropScience maintains a global network of research and development facilities. In the Crop Protection segment it identifies and develops safe and economically sustainable insecticides, fungicides and herbicides and carries its research projects in areas, such as plant health or stress tolerance. As of December 31, 2009, its active ingredient pipeline of Crop Protection contained 20 development projects, of which 10 was at an advanced stage and 10 at an early stage of development, and an additional 45 projects was undergoing early-stage research. Its operations are structured into six business operations units: four regional Crop Protection units plus the Environmental Science and BioScience units. Its insecticides include Confidor/ Admire, Calypso, Decis, Temik and Oberon. Its fungicides include Antracol, Fandango, Flint/Stratego/Sphere/Twist, Folicur and Previcur Energy. Its herbicides include Atlantis, Basta, Betanal, Fenikan, Hoestar, Husar, MaisTer, Puma. Its seed treatment products include Bariton, Gaucho, Lamarador, Poncho and Raxil.
Bayer MaterialScience
The Company supplies materials, such as polycarbonates and polyurethanes and system solutions for a range of everyday uses. It operates in three business units: Polyurethanes, Polycarbonates, and Coatings, Adhesives and Specialties. Its Coatings, Adhesives, Specialties producst include Desmodur, Bayhydur, Dispercoll and Artwalk. Its Polycarbonates include Makrolon, Makrofol / Bayfol, Fantasia and Bayblend. Its Polyurethanes include Multitec, Baydur, Bayflex, Baypreg and Vulkollan. Its Thermoplastic Polyurethanes include Desmopan / Texin.
Advisors' Opinion: - [By Henry Kawabe]
In June, Seattle Genetics announced it entered into a collaboration with Bayer HealthCare (BAYRY.PK) for access to its Seattle Genetics' auristatin-based ADC technology to create cancer drugs that home in on tumors and then deliver a toxic dose to their cells. The collaboration will generate upfront and option exercise fees of up to $20 million. Seattle Genetics is also eligible to receive up to approximately $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration.
- [By Bioassociate Consulting]
KYTH holds a collaboration agreement with Bayer's (BAYRY.PK) dermatology division to develop and commercialize ATX-101 outside the United States and Canada, and is eligible to receive up to $297m in additional regulatory and commercialization milestones, as well as escalating sales royalties in mid to high-teens. Bayer completed two pivotal Phase III trials of ATX-101 in Europe for the reduction of submental fat. During June 2012, Kythera released results from these studies, in which ATX-101 achieved a statistically significant reduction in submental fat based on clinician, patient and objective ratings.
Best Healthcare Equipment Stocks To Invest In 2014: Stellus Capital Investment Corp (SCM)
Stellus Capital Investment Corporation is an externally managed, closed-end, non-diversified management investment company. The Company was formed to originate and invest primarily in private middle-market companies.
The Company is focusing on a variety of industry sectors, including business services, energy, general industrial, government services, healthcare, software and specialty finance. Its investment activities will be managed by its investment adviser, Stellus Capital Management. It intends to originate and invest primarily in private middle-market companies through first lien, second lien, unitranche and mezzanine debt financing.
Advisors' Opinion: - [By Investing Caffeine]
With the stock market reaching all-time record highs (S&P 500: 1900), you would think there would be a lot of cheers, high-fiving, and back slapping. Instead, investors are ignoring the sunny, blue skies and taking off their rose-colored glasses. Rather than securely sleeping like a baby (or relaxing during a three-day weekend) with their investment accounts, people are biting their fingernails with clenched teeth, while searching for a market boogeyman in their closets or under their beds.If you don�� believe me, all you have to do is pick up the paper, turn on the TV, or walk over to the office water cooler. An avalanche of scary headlines that are spooking investors include geopolitical concerns in Ukraine & Thailand, slowing housing statistics, bearish hedge fund managers (i.e., Tepper Einhorn, Cooperman), declining interest rates, and collapsing internet stocks. In other words, investors are looking for things to worry about, despite record corporate profits and stock prices. Peter Lynch, the manager of the Magellan Fund that posted +2,700% in gains from 1977-1990, put short-term stock price volatility into perspective:��ou shouldn�� worry about it. You should worry what are stocks going to be 10 years from now, 20 years from now, 30 years from now.��ather than focusing on immediate stock market volatility and other factors out of your control, why not prioritize your time on things you can control. What investors can control is their asset allocation and spending levels (budget), subject to their personal time horizons and risk tolerances. Circumstances always change, but if people spent half the time on investing that they devoted to planning holiday vacations, purchasing a car, or choosing a school for their child, then retirement would be a lot less stressful. After realizing 99% of all the short-term news is nonsensical noise, the next important realization is stocks are volatile securities, which frequently go down -10 to -20%. As much
- [By Investing Caffeine]
DISCLOSURE: Sidoxia Capital Management (SCM) and some of its clients hold long positions in certain exchange traded funds (ETFs), but at the time of publishing SCM had no direct position in GS, SCHW, ICE, or any other security referenced in this article. No information accessed through the Investing Caffeine (IC) website constitutes investment, financial, legal, tax or other advice nor is to be relied on in making an investment or other decision. Please read disclosure language on IC Contact page.
Best Healthcare Equipment Stocks To Invest In 2014: Solitron Devices Inc (SODI)
Solitron Devices, Inc., incorporated on March 12, 1987, designs, develops, manufactures and markets solid-state semiconductor components and related devices primarily for the military and aerospace markets. The Company manufactures a variety of bipolar and metal oxide semiconductor (MOS) power transistors, power and controls hybrids, junction and power MOS field effect transistors (Power MOSFETS), field effect transistors and other related products. It's products are custom made pursuant to contracts with customers whose end products are sold to the United States government. The Company�� semiconductor products can be classified as active electronic components. The Company�� active electronic components include bipolar transistors and MOS transistors.
The Company�� semiconductor products are used as components of military, commercial, and aerospace electronic equipment, such as ground and airborne radar systems, power distribution systems, missiles, missile control systems, and spacecraft. Its products have been used on the space shuttle and on the spacecraft sent to the moon, to Jupiter (on Galileo) and, to Mars (on Global Surveyor and Mars Sojourner).
Power Transistors
The Company manufactures a variety of power bipolar transistors for applications requiring currents in the range of 0.1 ampere to 300 ampere or voltages in the range of 30 volts to 1000 volts. It also manufactures power diodes under the same military specification. In addition, it manufactures power N-Channel and P-Channel MOSFET transistors and is expanding that line in accordance with customers��requirements.
Hybrids
The Company manufactures thick film hybrids, which generally contain discrete semiconductor chips, integrated circuits, chip capacitors and thick film or thin film resistors. The hybrids are of the high-power type and are custom manufactured for military and aerospace systems. Some of the Company�� hybrids include high power voltage regulators, p! ower amplifiers, power drivers, boosters and controllers. The Company manufactures both standard and custom hybrids.
Voltage Regulators
Voltage regulators provide the power required to activate electronic components such as the integrated circuits. These circuits are found in all electronic devices from radar and missile systems to smart phones.
Field Effect Transistors
The Company manufactures about 30 different types of junction and MOS field effect transistor chips. They are used to produce over 350 different field effect transistor types. The Company�� field effect transistors conform to standard Joint Electronic Device Engineering Council designated transistors, commonly referred to as standard 2N number types. It manufactures both standard and custom field effect transistors.
The Competes with IXYS Corporation, Motorola Inc., International Rectifier, Microsemi Corporation, M.S. Kennedy Corporation, Natel Engineering Company and Sensitron Semiconductor.
Advisors' Opinion: - [By Geoff Gannon]
Solitron (SODI) sells at 74% of NCAV, has decent z- and f-scores, a FCF margin of 5.3% and an ROA of 12%.
Micropac (MPAD) sells at 83% of NCAV, has similar (slightly better) z- and f-scores, a FCF margin of 6%, but has ROA of 28%.
ADDvantage (AEY) sells at 95% of NCAV, has similar (in the ballpark) scores and FCF and ROA of 23%.
- [By Geoff Gannon] on the amount of stock you can buy and the position size you like. For me, I try not to start buying a stock that I think will never make up 10% of my portfolio. If you don�� mind having 5% positions in your portfolio, your portfolio can obviously be twice as big as mine and you can still consider buying the same small stocks I do. In terms of specific stocks, it depends on the amount of float and the volume the stock trades in an average month. We are really getting into specifics here. And I may be boring people. But if you�� like to hear more about the minutiae of how you actually buy and sell tiny stocks like these, let me know, and I��l do an article on the subject.
By the way, there is a hard and fast rule of thumb that it usually makes no sense to invest in a company with a market cap that is smaller than your portfolio. This is true for both fund and individual investors. Funds break it all the time. But, frankly, it is probably a waste of an analyst/fund manager�� time to even analyze such tiny positions relative to the size of the whole portfolio. Since even when we are discussing very small stocks we are still talking about millions and millions of dollars in market cap, this is hardly a concern for most individuals.
So, for individual investors, actual inability to acquire enough shares of a company to meaningful influence their portfolio is rarely the problem. If you bid for a stock month after month ��you��l get your shares.
The concern for individual investors is not whether buying enough shares is possible. The concern is how quickly and easily you can buy and sell. This is what we call ��iquidity.��/p>
Instead of thinking about stocks as liquid or illiquid, you should think in terms of your portfolio and your liquidity needs. It doesn't make much sense to use what I'll call an "objective" (as in stock-oriented) approach to liquidity rather than a "subjective" (as in investor-oriented) approach to liquidity.
< - [By Geoff Gannon] strong>OPT-Sciences (OPST)
Micropac
Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.
ADDvantage
ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.
By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.
That�� pretty typical in the world of net-nets.
Solitron
Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO ��we��e still talking about a company where one person has a lot of control. Solitron only has three directors. Saraf is the chairman, CEO, president, CFO and treasurer. Neither of the other two directors joined the board within the last 15 years. So, we aren�� talking about a lot of tumult at the top.
In fact, profitable net-nets seem to be especially common candidates for abandoning the responsibilities of a public company without actually getting taken private.
OPT-Sciences
This
Best Healthcare Equipment Stocks To Invest In 2014: Leucadia National Corporation(LUK)
Leucadia National Corporation, through its subsidiaries, engages in manufacturing, land based contract oil and gas drilling, gaming entertainment, real estate, medical product development, and winery operations in the United States and internationally. Its manufacturing operations include remanufacturing, manufacturing, and/or distribution dimension lumber, home center boards for retailers, pine decking, and other specialty wood products; and manufacturing and marketing lightweight plastic netting used in building and construction, erosion control, packaging, agricultural, carpet padding, filtration, and consumer products. The company?s land based contract oil and gas drilling operations include the provision of drilling services to independent oil and natural gas exploration and production companies in the Mid-Continent region of the United States, including Oklahoma, Texas, Arkansas, Louisiana, and Kansas. As of December 31, 2010, it had 38 drilling rigs. The company?s g aming entertainment operations consist of owning the Hard Rock Hotel & Casino Biloxi located in Biloxi, Mississippi, which consists of 325 rooms and suites, 1,268 slot machines, 52 table games, 6 live poker tables, 5 restaurants, and spa. Its real estate activities include investment in commercial properties, residential land development projects, and other unimproved land. The company?s medical product development operations comprise the development of MP4OX that has completed a phase II proof of concept clinical trial and is a solution of cell-free hemoglobin, administered intravenously to provide oxygen delivery to oxygen deprived tissues. In addition, Leucadia National Corporation engages in the production and sale of wines; and investment and evaluation of gasification projects to convert various types of low grade fossil fuels into energy products. The company was founded in 1854 and is based in New York, New York.
Advisors' Opinion: - [By John Reeves]
Author and investor William Thorndike recently wrote a book looking at eight CEOs who outdid the S&P 500. In this video, John Reeves looks at what distinguished these CEOs. One characteristic: decentralized operations. CEOs like Warren Buffett allow managers to do their jobs without micro-managing them. These top CEOs also are frugal and don't spend a lot on themselves. They also tend to be skeptical and avoid the limelight. Perhaps, most importantly, exceptional CEOs don't follow the crowd. They make their own decisions without influence from Wall Street.� Some companies that Thorndike recommends are Leucadia National� (NYSE: LUK ) and Markel Corporation (NYSE: MKL ) . Thorndike also likes Amazon (NASDAQ: AMZN ) as a great example of a company doing its own thing and with a healthy disregard for Wall Street experts.
- [By Roberto Pedone]
Another holding company that insiders are loading up on here is Leucadia National (LUK), which invests in beef processing, manufacturing, telecommunications, gaming, real estate, energy, medical product development and winery operations. Insiders are buying this stock into notable strength, since shares are up 12.6% so far in 2013.
Leucadia National has a market cap of $9.7 billion and an enterprise value of $11.2 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 8.34. This is not a cash-rich company, since the total cash position on its balance sheet is $18.82 billion and its total debt is $20.20 billion. This stock currently sports a dividend yield of 0.90%.
A director just bought 40,000 shares, or about $1.06 million worth of stock, at $26.55 per share.
From a technical perspective, LUK is currently trending just below its 50-day moving average and just above its 200-day moving average, which is neutral trendwise. This stock has been consolidating for the last month, with shares moving sideways between $27.98 on the upside and $26.38 on the downside. A high-volume move above the upper-end of its recent sideways trading chart pattern could trigger a big breakout trade for shares of LUK.
If you're in the bull camp on LUK, then look for long-biased trades as long as this stock is trending above its 200-day at $26.30 or above more support at $25.61, and then once it breaks out above some near-term overhead resistance levels at $27.42 to $27.98 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 1.34 million shares. If that breakout triggers soon, then LUK will set up to re-test or possibly take out its next major overhead resistance levels at $31.78 to $32.36 a share.
- [By Brendan Mathews]
If�The Outsiders�featured one more CEO, we asked, who would it be? Thorndike said he wanted to write an extra chapter for the book on Ian Cumming and Joe Steinberg of�Leucadia National� (NYSE: LUK ) . They have an awesome track record and embody many of the Outsiders' principles, but they also didn't want to be in the book. And without their cooperation, he couldn't write it. (Cumming has since retired, but Steinberg is now Leucadia's chairman of the board.)
- [By Monica Wolfe]
Leucadia National Corporation (LUK)
Berkowitz�� fifth largest position goes to Leucadia National Corporation where the guru holds 6.4% of his total portfolio. Berkowitz owns 18,664,999 shares of Leucadia, representing 7.63% of the company�� shares outstanding.
Best Healthcare Equipment Stocks To Invest In 2014: Medtronic Inc (MDT)
Medtronic, Inc. (Medtronic), incorporated on April 23, 1957, is engaged in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. As of April, 27, 2012, the Company functions in two operating segments that manufacture and sells device-based medical therapies. The Company's operating segments include Cardiac and Vascular Group, which consists of Cardiac Rhythm Disease Management (CRDM) and CardioVascular, and Restorative Therapies Group, which consists of Spinal, Neuromodulation, Diabetes and Surgical Technologies. Medtronic serves hospitals, physicians, clinicians, and patients in more than 120 countries worldwide. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. In August 2013, Medtronic, Inc. announced the closing of the acquisition of Cardiocom. Effective September 3, 2013, Medtronic Inc acquired a 30% stake in NGC Medical SpA.
Cardiac Rhythm Disease Management
CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. The Company's principal products offered by CRDM business include Implantable Cardiac Pacemakers (Pacemakers), Implantable Cardioverter Defibrillators (ICDs), Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps), AF Products, Diagnostics and Monitoring Devices and Patient Management Tools. The Company's pacemaker systems are compatible with certain magnetic resonance imaging (MRI) machines. This includes the Revo MRI SureScan with United States Food and Drug Administration approval and the Advisa and Ensura MRI SureScan models with Conformite Europeene (CE)! Mark approval. Medtronic also continues to market the Adapta product family, which includes the Adapta, Versa, Sensia, and Relia models.
The Medtronic ICDs is the Protecta family with SmartShock technology, including the Lead Integrity Alert, a technology designed to improve the detection of lead fractures. Devices in the ICD family are the Protecta XT, Protecta, Cardia, and Egida models. Medtronic also continues to market the Secura and Maximo II devices. The Medtronic CRT-Ds is the Protecta family with SmartShock technology, including Protecta XT and Protecta, and the CRT-P devices are Consulta and Syncra. Medtronic also continues to market the Consulta, Cardia, Egida, and Maximo II CRT-D devices. In addition to these devices, Medtronic has an offering of left heart leads and delivery catheters with its Attain family of products. The Company's portfolio of AF products includes the Arctic Front Cardiac CryoAblation Catheter designed to treat paroxysmal AF by performing pulmonary vein isolation. The Company also offers the Reveal XT Insertable Cardiac Monitor, which is designed to identify and quantify episodes of AF. The Reveal DX and Reveal XT Insertable Cardiac Monitors devices are used to record the heart's electrical activity before, during, and after transient symptoms such as syncope and palpitations to help provide a diagnosis. It has a number of patient management tools, such as CareLink, Paceart, and CardioSight Service. CareLink enables patients to transmit data from their pacemaker, ICD, CRT-D, or Insertable Cardiac Monitors using a portable monitor that is connected to a standard telephone line or cellular network using the Medtronic M-Link accessory.
The Company competes with St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc. and Sorin Group.
CardioVascular
CardioVascular is comprised of three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. The Coronary business includes therapies to treat ! coronary ! artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, along with a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories. The products offered by its Coronary business include Percutaneous Coronary Intervention (PCI) and Renal Denervation. The Endovascular and Peripheral business is comprised of a range of products and therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease (PVD). The Company's products include endovascular stent graft systems, embolic protection systems, and stent systems for the treatment of narrowed iliac arteries. The products offered by the Company's Endovascular and Peripheral business include Endovascular Stent Grafts and Peripheral Vascular Intervention (PVI). The Structural Heart business offers a range of products and therapies to treat a variety of heart valve disorders. The Company's products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products. The Company's principal products offered by its Structural Heart business include Heart Valves, Transcatheter Heart Valves, Arrested Heart Surgery, Beating Heart Surgery and Surgical Ablation.
The Company competes with Abbott Laboratories, Boston Scientific, and Johnson & Johnson, Cook, Inc., W. L. Gore & Associates, Inc., Endologix, Inc., C.R. Bard, Inc., Edwards LifeSciences Corporation, St. Jude, Terumo Medical Corporation and Sorin Group.
Spinal
The Company's Spinal business develops, manufactures, and markets a range of medical devices and implants used in the treatment of the spine and musculoskeletal system. The Company's products and therapies treat a range of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumours, fractures ! of the sp! ine, and stenosis. The Company's Spinal business also provides biologic solutions for the dental and orthopedic markets. The Company's Spinal products are used in spinal fusion of both the thoracolumbar region, referring to the mid to lower vertebrae, as well as of the cervical region, or upper spine and neck vertebrae. Products used to treat spinal conditions include rods, pedicle screws, hooks, plates, and interbody devices, as well as biologics products, primarily bone growth substitutes including bone graft extenders and structural allografts such as dowels and wedges. The products offered by the Company's Spinal business include Thoracolumbar Products, Cervical Products and Biologics Products.
The Company competes with DePuy Spine, Inc., Synthes, Inc., Stryker Corporation, NuVasive, Inc., Globus Medical, Inc., Zimmer, Inc., Alphatec Spine, Inc., Orthofix International N.V., Biomet, Inc. and Johnson & Johnson.
Neuromodulation
The Company's Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. The l products offered by the Company's Neuromodulation business includes Neurostimulators for Chronic Pain, Implantable Drug Delivery Systems, Deep Brain Stimulation (DBS) Systems and Urology, Fecal, & Gastroenterology Devices. The Company's portfolio of products includes the RestoreSensor (rechargeable), with the Company's AdaptiveStim technology, as well as the RestoreULTRA (rechargeable), RestoreADVANCED (rechargeable), and PrimeADVANCED (non-rechargeable) neurostimulation systems. The SynchroMed II Programmable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.
DBS uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver carefully controlled electrical stimulation to precisely targeted areas in the brain. The Company's family of Activa Neurostimulators for DBS includes Activa SC (single-channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable). The Company's therapeutic portfolio for urology and gastroenterology includes the InterStim Therapy System, which treats the symptoms of overactive bladder, urinary retention, and chronic fecal incontinence, and the Enterra Therapy System for the treatment of chronic nausea and vomiting caused by gastroparesis of diabetic or idiopathic origin for drug refractory patients.
The Company's competes with Boston Scientific, St. Jude., Urologix, Inc. and Allergan.
Diabetes
The Company's Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. The products offered by the Company's Diabetes business includes Integrated Diabetes Management Solutions, Professional CGM and CareLink Therapy Management Software. Outside the United States, the Company offers its Paradigm Veo System, an integrated system that includes a Low Glucose Suspend feature that automatically suspends insulin delivery when glucose levels become too low. In the United States, the Company offers the Paradigm Revel System, which incorporates new CGM features, including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events. Medtronic offers physicians a Professional CGM product called the iPro CGM and iPro2 Professional CGM. The Company offers Web-based therapy management software solutions, including CareLink Personal software for patients and CareLink Pro software, to helps patients and their health care prov! iders con! trol their diabetes.
The Company competes with DexCom, Inc., Insulet Corporation, Johnson & Johnson and Roche Ltd.
Surgical Technologies
The Company's Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. The products offered by the Company's Surgical Technologies business includes ENT, Neurological Technologies, Navigation and Advanced Energy. The ENT products treat diseases and conditions, such as NIM Nerve Monitoring Systems, Fusion ENT Navigation System, Hydrodebrider Endoscopic Sinus Irrigation System, Meniett Device for Meniere's Disease, Pillar Procedure for Snoring and Sleep Apnea, and Repose System for Obstructive Sleep Apnea. The Neurological Technologies products treat certain neurological disorders and conditions, such as Midas Rex Spine Shaver, the Midas Rex MR7 Pneumatic Platform, the Midas Rex Legend EHS High Speed Surgical Drill, the Strata Family of Adjustable Valves for the treatment of Hydrocephalus, Duet External Drainage & Monitoring System, the IPC System, and the Subdural Evacuating Port System.
The Navigation products are used in cranial, spinal, sinus, and orthopedic surgeries, such as the StealthStation S7 Navigation and i7 Integrated Navigation Systems, the O-Arm 2D/3D Surgical Imaging System, and the PoleStar Surgical MRI System. The products make up the Advanced Energy business: PEAK Surgery System, a tissue dissection system that consists of the PEAK PlasmaBlade and the PULSAR Generator and is cleared for use in a variety of settings, including ENT, plastic reconstructive and general surgery; and the Aquamantys System, which uses patented Transcollation technology to ! provide h! aemostatic sealing of soft tissue and bone and is cleared for use in a range of surgical procedures, including orthopedic surgery, spine, solid organ resection and thoracic procedures.
The Company competes with Gyrus ACMI, Stryker Corporation, Johnson & Johnson, Integra LifeSciences Holdings Corporation, BrainLAB, Inc., GE Healthcare, Siemens Medical Solutions USA, Inc., Philips Medical Systems, Covidien and ArthroCare Corporation.
Advisors' Opinion: - [By Dan Carroll]
Sales in the division's surgical care, diagnostics, and diabetes care businesses declined last year, while cardiovascular device sales slumped more than 13%. Cardiovascular device sales -- particularly in the cardiac rhythm management, or CRM, industry --�have been on the decline lately industrywide; Medtronic (NYSE: MDT ) , one of J&J's largest device competitors, has seen its CRM revenue fall 3% over the last nine months, and it's done far better than worse-off rivals in the industry. Don't expect this business to turn around quickly for J&J.
- [By Ben Levisohn]
While shares of Volcano have dropped 15% to $20.74, large-cap medical device companies are having a solid day. Boston Scientific (BSX) has gained 1.4% to 11.74, St. Jude Medical (STJ) has risen 0.9% to $48.13 and Medtronic (MDT) has ticked up 0.1% to $57.73.
- [By Dan Burrows]
However, it’s not such a big deal for behemoths like Medtronic (MDT) and, yes, Stryker. With MDT and SYK doing about $17 billion and $9 billion in annual sales, respectively, the tax represents a large bill in dollar terms … but it’s hardly a crippling blow to revenue (or margins or profits) on a percentage basis.
- [By Dan Carroll]
Edwards' stock's massive plunge today was probably too much for the miss, but the cardiovascular market overall has been tough on medical-device companies recently. St. Jude Medical (NYSE: STJ ) reported falling sales in its most recent quarterly report, primarily because of cardiovascular-related revenue on the decline, and Medtronic (NYSE: MDT ) , a competitor of Edwards' in the heart valve market with its CoreValve device, could still threaten the Sapien's sales despite a court ruling recently that judged the CoreValve to have infringed on one of Edwards' patents.
Best Healthcare Equipment Stocks To Invest In 2014: Hercules Offshore Inc.(HERO)
Hercules Offshore, Inc., together with its subsidiaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry in the U.S. Gulf of Mexico and internationally. Its services comprise oil and gas exploration and development drilling, well services, platform inspection, and maintenance and decommissioning services in various water provinces. As of May 10, 2011, the company owned and operated a fleet of 50 jackup rigs, 17 barge rigs, 65 liftboats, 3 submersible rigs, and 1 platform rig. It serves national oil and gas companies, integrated energy companies, and independent oil and natural gas operators. The company was founded in 2004 and is headquartered in Houston, Texas.
Advisors' Opinion: - [By Taylor Muckerman and Joel South]
On an island by itself
Within the offshore market, Hercules Offshore (NASDAQ: HERO ) has isolated itself as a jack-up rig specialist. Even more specialized is the fact that 29 of its 38 rigs are currently drilling for fossil fuels in the Gulf Coast region. While many companies left the area after the Macondo incident, Hero decided to stick around and many expect this diligence to payoff. Tomorrow's release will certainly go a long way toward proving this optimistic group right or wrong.
- [By Lee Jackson]
Hercules Offshore Inc. (NASDAQ: HERO) is the top small cap name to buy for 2014. The company provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide. The company operates through five segments: Domestic Offshore, International Offshore, Inland, Domestic Liftboats and International Liftboats. The Deutsche Bank price target is posted at $10, and the consensus number is at $9.50. Hercules closed Monday at $6.39.
